Infectious Disease Drug Development and Molecular Pharmacology – ZRG1 DCAI 81
The Infectious Disease Drug Development and Molecular Pharmacology (DCAI (81)) study section reviews applications that are concerned with the identification of novel therapeutic agents to combat bacterial, fungal, parasitic and viral (excluding HIV) infections using biochemical, pharmacological, structural, cell-based, and animal model approaches. Emphasis is on early-stage optimization and molecular characterization of all classes of therapeutics.
Review Dates
Topics
- Early-stage optimization of therapeutic leads to increase efficacy
- Molecular characterization of anti-infective agents, including mechanism of action, structural characterization, and confirmation of target engagement
- Molecular characterization of drug combination regimens and repurposed drugs
- Early preclinical drug toxicity and pharmacokinetic/pharmacodynamic studies
Shared Interests and Overlaps
There are substantial shared interests in early-stage drug characterization with Drug Discovery and Molecular Pharmacology A (DMPA). Applications that emphasize initial discovery methods are reviewed in DMPA, whereas applications that emphasize optimization of lead therapeutics are reviewed in DCAI (81).
There are shared interests in drug development with Advancing Therapeutics B (ATB). Applications that emphasize late-stage drug development efforts such as diversification, optimization and preclinical toxicity and pharmacokinetic/pharmacodynamic studies may be reviewed in ATB. Applications that emphasize early-stage drug optimization and characterization of mechanism of action may be reviewed in DCAI (81).
There are shared interests in the early stages of anti-infective therapeutic drug development with Chemical Synthesis & Biosynthesis (CSB). Applications that emphasize synthetic and biosynthetic approaches with limited biological assessments are reviewed in CSB. Applications that couple synthetic approaches with extensive biological analyses may be reviewed in DCAI (81).
